In United States v. Caronia (2012), a criminal misbranding, off-label promotion case, the Second Circuit ruled that the Food and Drug Administration’s (FDA) enforcement of pharmaceutical manufacturers violates the First Amendment. Pharmaceutical manufacturers view Caronia as a watershed for the end of deference to FDA’s oversight role as arbiter of off-label medication usage determinations and perhaps, the beginning of the demise of preemption. The central constitutional question is can FDA’s off-label promotion prohibition withstand First Amendment scrutiny of free speech in general and commercial speech in particular? Is a new paradigm required to promulgate a framework of laws and regulations that will minimize healthcare costs and patient injuries while allowing truthful off-label promotion?
Drug Amendments of 1962 (Kefauver-Harris Amendments), Pub. L. No. 87-781, 76 Stat. 780, 781 (codified as amended 21 U.S.C. § 505(b) (2008).
3.
KlasmeierCRedishMH. Off-label prescription advertising, the FDA and the First Amendment: A study in the values of commercial speech protection. Am J Law Med2011; 37: 315–357.
4.
QureshiZP. Enforcement actions involving Medicaid fraud and abuse, 1996-2009. Arch Int Med2011; 171(8): 785–787.
5.
RoehrB. GlaxoSmithKline is fined record $3bn in US. Br Med J2012; 345: e4568–e4568.
6.
Silverman E. Off-label marketing: free speech or illegal promotion? Br Med J 346: f320.
7.
KesselheimAS. Off-label drug use and promotion: balancing public health goals and commercial speech. Am J Law Med2011; 37: 225–257.
US Dept HHS. Food and Drug Administration. FDA guidance for industry. Good reprint practices for the distribution of medical journal articles and medical or scientific reference publications on unapproved uses of approved drugs and approved or cleared medical devices, http://www.fda.gov/ohrms/dockets/98fr/fda-2008-d-0053-gdl.pdf (2009, accessed 30 November 2013).
11.
US Dept HHS. Food and Drug Administration. FDA guidance for industry. Industry-supported scientific and educational activities, December 1997.
Central Hudson Gas & Electric Corp. v. Public Service Commission of New York, 447 U.S. 557, 566 (1980).
14.
GreenwoodK. The ban on “off-label” pharmaceutical promotion: constitutionally permissible prophylaxis against false or misleading commercial speech?Am J Law Med2011; 37: 278–298.
15.
U.S. CONST. art I. §8, cl. 3.
16.
U.S. CONST. art I. §8, cl. 18.
17.
Thompson v. W. States Med. Ctr., 535 U.S. 357 (2002).
18.
Washington Legal Foundation v. Friedman, 13 F. Supp.2d 51, 55 (D.D.C. 1998).
19.
Washington Legal Foundation v. Henney, 56 F. Supp. 2d 81 (D.D.C. 1999).
20.
44 Liquormart, Inc. v. Rhode Island, 517 U.S. 484, 506 (1996).
21.
Sorrell v. IMS Health, Inc, 131 S.Ct. 2653 (2011).
22.
HallRFSobotkaES. Inconsistent government policies: Why FDA off-label regulation cannot survive First Amendment review under greater New Orleans. Food Drug Law J2007; 62: 1–46.
23.
Singer N. Botox maker’s suit cites free speech. New York Times, 3 October 2009, at B3.
24.
Complaint United States ex rel. Lang and Rushin v. Allergan, Inc., No. 1:07-ev-1288 (N.D. Ga June 5, 2007).
25.
United States v. Caputo, 288 F. Supp.2d 912 (N.D. Ill. 2003).
26.
United States v. Caronia, 703 F.3d 149 (2nd Cir. December 3, 2012).
27.
Food Drug Cosmetic Act, 21 C.F.R. §§ 331(a) and 352(f)(1).
28.
U.S. v. Caronia, 576 F. Supp.2d 385, 401 (E.D.N.Y. 2008).
29.
Brief for United States as Amicus Curiae, United States v. Caronia, No.09-5006, 2010 WL 6351497 (C.A.2).
30.
Fed. Reg. 11,022 (June 8, 1971).
31.
KesselheimASMelloMMAvornJ. Regulation of off-label drug promotion under attack. J Am Med Assoc2013; 309(5): 445–446.
U.S. ex rel. Thompson et al v. Par Pharmaceutical, et al, Civil Action No. cv-09-3526 (D.N.J.).
34.
Par Pharm., Inc v. U.S. No. 11-cv-01820-RC (D.D.C. filed October 14, 2011).
35.
Walsh MA. (April 2, 2013) United States: FDA marketing: Par v. US - Pay no attention to the man behind the curtain - Why is the government trying to strike its own statements from the public record? Food Drug Cosmetic Blog, http://www.mondaq.com/united states/x/229786/food+drugs+law/FDA+Marketing+PAR (accessed 30 November 2013).
BoumilMM. Off-label marketing and the First Amendment. N Engl J Med2013; 368: 103–105.
39.
Ball FR and Duffy EM. United States v. Caronia: A brief look at broader implications for the food industry. Food & Drug Law Institute. March/April 2013: 20–22, www.fdli.org (accessed 30 November 2013).
40.
HertelM. FDA’s oversight of the promotion of drugs for off-label uses. Albany Law J Sci Technol2009; 19(3): 627–632.
41.
Copland J and Howard P. Off-label, not off-limits: The FDA needs to create a safe harbor for off-label drug use. vol. 15. New York: Manhattan Institute for Policy Research, 2012, pp. 1–6.
